Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 US Penny Stocks With Market Caps Over $30M

In This Article:

As the U.S. markets experience fluctuations with major indices like the Dow Jones and Nasdaq reacting to earnings reports, investors are keenly observing economic indicators that could influence future interest rate decisions. In this context, penny stocks—typically smaller or newer companies—remain an intriguing investment area despite their somewhat outdated label. These stocks can offer surprising value and potential for growth, especially when backed by strong financials, making them a noteworthy consideration for those seeking opportunities beyond the mainstream market names.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

QuantaSing Group (NasdaqGM:QSG)

$3.08

$93.03M

★★★★★★

BAB (OTCPK:BABB)

$0.8999

$6.54M

★★★★★★

Kiora Pharmaceuticals (NasdaqCM:KPRX)

$3.40

$9.63M

★★★★★★

Inter & Co (NasdaqGS:INTR)

$4.56

$1.91B

★★★★☆☆

ZTEST Electronics (OTCPK:ZTST.F)

$0.3052

$11.04M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.57

$50.16M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

BTCS (NasdaqCM:BTCS)

$2.78

$43.03M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.14

$20.75M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.9143

$81.09M

★★★★★☆

Click here to see the full list of 713 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Cumberland Pharmaceuticals

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that acquires, develops, and commercializes prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally, with a market cap of $37.49 million.

Operations: The company's revenue is primarily generated from its specialty pharmaceutical products, totaling $36.79 million.

Market Cap: $37.49M

Cumberland Pharmaceuticals, with a market cap of US$37.49 million, remains unprofitable but has reduced losses over the past five years. The company holds more cash than its total debt and maintains a cash runway exceeding three years if current free cash flow trends persist. Recent FDA approval for a streamlined dosing regimen of Acetadote® enhances its product portfolio, potentially improving patient outcomes. However, increased debt-to-equity ratio and heightened share price volatility pose challenges. Despite these issues, Cumberland's seasoned management and board provide stability as they navigate the competitive pharmaceutical landscape.